8-K: Zynex Appoints Steven Dyson as New CEO, Founder Thomas Sandgaard Transitions to Chairman Role

Zynex, Inc. announced the appointment of Steven Dyson as its new Chief Executive Officer, effective August 18, 2025, succeeding founder Thomas Sandgaard who will remain Chairman of the Board.

Summary

• Steven Dyson has been appointed Chief Executive Officer of Zynex, Inc., with his tenure commencing on August 18, 2025.
• Thomas Sandgaard, the company's founder, will retire from his CEO position on August 18, 2025, but will continue his active involvement as Chairman of the Board and Chair of the Board's Technology Committee.
• Mr. Dyson, 52, brings over 25 years of experience in global healthcare investment and the medical technology sector, having previously served as Global Co-Head of Healthcare at Apax Partners from 2012 to 2025.
• His employment agreement, effective May 23, 2025, stipulates an initial annual base salary of $750,000 and eligibility for an annual discretionary bonus of up to 100% of his base salary, contingent on performance criteria.
• Mr. Dyson is also entitled to a success fee, equal to 5% of the total cash and non-cash consideration received by common stockholders in a change of control event, specifically on amounts exceeding a $100,000,000 baseline threshold.
• New indemnification agreements were executed with all officers and directors, effective June 30, 2025, to enhance protection against personal liability.
• In the event of termination without cause or with good reason, Mr. Dyson is eligible for a severance amount equal to 18 months of his base salary, paid over 18 months, and 12 months of COBRA health continuation payments.

Sentiment

Score: 8

Explanation: The document announces a strategic leadership change with a highly experienced new CEO and the founder remaining involved, which is generally positive for continuity and future growth. The detailed compensation and governance structures indicate a well-planned transition. No explicit negative financial or operational news is present, suggesting a stable outlook for this transition.

Positives

• Appointment of a highly experienced CEO, Steven Dyson, with over 25 years in global healthcare investment and medical technology, including leadership at Apax Partners, which suggests a strategic focus on growth and value creation.
• Founder Thomas Sandgaard will remain actively involved as Chairman of the Board and Chair of the Technology Committee, ensuring continuity, leveraging his long-standing expertise, and providing a smooth leadership transition.
• The new CEO's compensation structure includes a significant success fee tied to a change of control, potentially aligning his interests with shareholder value creation in such an event.
• The company is explicitly refocusing its business strategy toward a more optimized payer mix and aims to return to a strong growth trajectory under the new leadership.
• New indemnification agreements for officers and directors enhance the company's ability to attract and retain top talent by providing robust protection against personal liability.

Risks

• Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the company's control.
• The company's ability to achieve its strategic objectives depends on factors such as obtaining CE marking for new products and the acceptance of new and existing products by doctors and hospitals.
• Competition from larger competitors with greater financial resources poses a risk to market share and growth.
• Dependence on reimbursement for products from health insurance companies introduces financial risk due to potential changes in coverage policies or rates.
• Reliance on first-party manufacturers to produce products on time and to specifications could lead to supply chain disruptions if not managed effectively.
• The need to continuously keep pace with technological changes in the medical device sector requires ongoing investment in research and development.
• General economic factors, such as interest rate fluctuations, and broader market conditions could impact the company's financial performance.
• The employment agreement includes restrictive covenants, such as non-solicitation of employees and service providers, non-compete clauses in the Restricted Territory (USA) for specific businesses, and non-solicitation of customers, all for 18 months post-termination, which could limit the new CEO's future professional activities.
• There is a potential for the company to establish a permanent establishment in the United Kingdom (PE), which would necessitate amendments to the employment agreement to comply with UK laws, potentially altering commercial and legal terms.

Future Outlook

The company aims to refocus its business strategy towards a more optimized payer mix and return to a strong growth trajectory under the new leadership. Forward-looking statements indicate ongoing efforts in product development, market acceptance, and managing competitive and economic factors, while also acknowledging the inherent uncertainties and risks in these endeavors.

Management Comments

• "I am excited to step back from day-to-day operations and continue contributing as Chairman." Thomas Sandgaard
• "Steven brings deep expertise and a proven track record in the medical sector. His leadership will be instrumental as we refocus our business strategy toward a more optimized payer mix and work to return Zynex to a strong growth trajectory." Thomas Sandgaard
• "I'm honored to join the Zynex team at this exciting time in the Company's history and to have the opportunity to lead the Company back to a strong growth trajectory." Steven Dyson
• "Zynex's strong foundation, built by Thomas over many years, provides an excellent platform to deliver exceptional value for all our stakeholders." Steven Dyson

Industry Context

The appointment of a new CEO with extensive experience in global healthcare investment and medical technology suggests Zynex is positioning itself for strategic growth, potentially through mergers, acquisitions, or significant market expansion. This aligns with broader trends of consolidation and innovation prevalent in the medical device sector. The stated focus on an 'optimized payer mix' indicates an adaptation to evolving healthcare reimbursement landscapes and a strategic effort to enhance revenue stability and profitability within the industry.

Comparison to Industry Standards

• Steven Dyson's background as Global Co-Head of Healthcare at Apax Partners, a prominent global private equity firm, with experience in acquiring, growing, and exiting numerous healthcare and medtech companies (e.g., KCI, Rodenstock, Healthium Medtech, Unilabs, Neuraxpharm), suggests a strategic shift towards leveraging private equity-style growth and value creation methodologies, which is a common practice in mature and consolidating industries.
• The compensation structure for the new CEO, including a substantial base salary, performance-based bonus potential up to 100% of base salary, and a success fee tied to a change of control, is competitive and aligns with typical executive compensation packages for CEOs of publicly traded medical technology companies, particularly those with a background in private equity, where such incentive structures are prevalent to drive significant value creation.
• The implementation of new indemnification agreements and the inclusion of standard restrictive covenants (non-compete, non-solicitation) in the employment agreement are consistent with corporate governance best practices and legal protections commonly adopted by companies in the medical technology industry to safeguard proprietary information and business interests during executive transitions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of a new CEO with a strong background in healthcare investment and a compensation structure tied to a change of control could signal a strategic focus on maximizing shareholder value and potentially lead to future growth or M&A activity.
• Employees: A leadership transition may bring new strategic direction, operational focus, and potential changes in corporate culture or priorities.
• Customers: The company's stated aim to return to a strong growth trajectory and optimize its payer mix could lead to improved product offerings, enhanced service, and more stable business relationships.
• Suppliers/Creditors: A stable and strategically focused leadership team can positively impact the company's financial health and long-term viability, benefiting its relationships with suppliers and creditors.

Next Steps

• Steven Dyson will commence his employment as Chief Executive Officer on August 18, 2025.
• Thomas Sandgaard will continue his active involvement as Chairman of the Board and Chair of the Board's Technology Committee.
• The Compensation Committee will establish the specific performance criteria for Steven Dyson's annual discretionary bonus.
• The company will continue its efforts to refocus its business strategy toward a more optimized payer mix and return to a strong growth trajectory.
• The company is committed to maintaining directors and officers liability insurance policies to provide ongoing coverage.

Key Dates

Recommendation

Keywords

Zynex, ZYXI, CEO Appointment, Steven Dyson, Thomas Sandgaard, Medical Technology, Healthcare Investment, Corporate Governance, Executive Compensation, SEC Filing, 8-K, Leadership Change, Indemnification Agreement, Nasdaq